A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
|Articles|June 6, 2012
Supreme Court: Decision Nears on 'Obamacare'
Advertisement
The Supreme Court is expected to announce its ruling on the Affordable Care Act (ACA) this month, and with the countdown started speculation about the impact of that decision is heating up on both sides of the "Obamacare" debate.
And both sides predict disaster for doctors -- massive disruption if the law is struck down -- or if it is upheld.
Read the full story:
Source: MedPage Today
Advertisement
Related to this article
Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
5